Current studies have provided substantial evidence that multiple FXR agonists could ameliorate the gut microbiota, suppress BA synthesis and metabolism, and relieve liver fibrosis progression in animal models with cholestasis (Yan et al. 2021; Xiang et al. 2021). The gene discussed is NR1H4; the disease is Hepatic fibrosis.